Cargando…

Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains

Systemic light chain (AL) amyloidosis is a fatal protein misfolding disease in which excessive secretion, misfolding, and subsequent aggregation of free antibody light chains eventually lead to deposition of amyloid plaques in various organs. Patient-specific mutations in the antibody V(L) domain ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Rottenaicher, Georg J., Weber, Benedikt, Rührnößl, Florian, Kazman, Pamina, Absmeier, Ramona M., Hitzenberger, Manuel, Zacharias, Martin, Buchner, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949129/
https://www.ncbi.nlm.nih.gov/pubmed/33508322
http://dx.doi.org/10.1016/j.jbc.2021.100334
_version_ 1783663496699838464
author Rottenaicher, Georg J.
Weber, Benedikt
Rührnößl, Florian
Kazman, Pamina
Absmeier, Ramona M.
Hitzenberger, Manuel
Zacharias, Martin
Buchner, Johannes
author_facet Rottenaicher, Georg J.
Weber, Benedikt
Rührnößl, Florian
Kazman, Pamina
Absmeier, Ramona M.
Hitzenberger, Manuel
Zacharias, Martin
Buchner, Johannes
author_sort Rottenaicher, Georg J.
collection PubMed
description Systemic light chain (AL) amyloidosis is a fatal protein misfolding disease in which excessive secretion, misfolding, and subsequent aggregation of free antibody light chains eventually lead to deposition of amyloid plaques in various organs. Patient-specific mutations in the antibody V(L) domain are closely linked to the disease, but the molecular mechanisms by which certain mutations induce misfolding and amyloid aggregation of antibody domains are still poorly understood. Here, we compare a patient V(L) domain with its nonamyloidogenic germline counterpart and show that, out of the five mutations present, two of them strongly destabilize the protein and induce amyloid fibril formation. Surprisingly, the decisive, disease-causing mutations are located in the highly variable complementarity determining regions (CDRs) but exhibit a strong impact on the dynamics of conserved core regions of the patient V(L) domain. This effect seems to be based on a deviation from the canonical CDR structures of CDR2 and CDR3 induced by the substitutions. The amyloid-driving mutations are not necessarily involved in propagating fibril formation by providing specific side chain interactions within the fibril structure. Rather, they destabilize the V(L) domain in a specific way, increasing the dynamics of framework regions, which can then change their conformation to form the fibril core. These findings reveal unexpected influences of CDR-framework interactions on antibody architecture, stability, and amyloid propensity.
format Online
Article
Text
id pubmed-7949129
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-79491292021-03-19 Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains Rottenaicher, Georg J. Weber, Benedikt Rührnößl, Florian Kazman, Pamina Absmeier, Ramona M. Hitzenberger, Manuel Zacharias, Martin Buchner, Johannes J Biol Chem Research Article Systemic light chain (AL) amyloidosis is a fatal protein misfolding disease in which excessive secretion, misfolding, and subsequent aggregation of free antibody light chains eventually lead to deposition of amyloid plaques in various organs. Patient-specific mutations in the antibody V(L) domain are closely linked to the disease, but the molecular mechanisms by which certain mutations induce misfolding and amyloid aggregation of antibody domains are still poorly understood. Here, we compare a patient V(L) domain with its nonamyloidogenic germline counterpart and show that, out of the five mutations present, two of them strongly destabilize the protein and induce amyloid fibril formation. Surprisingly, the decisive, disease-causing mutations are located in the highly variable complementarity determining regions (CDRs) but exhibit a strong impact on the dynamics of conserved core regions of the patient V(L) domain. This effect seems to be based on a deviation from the canonical CDR structures of CDR2 and CDR3 induced by the substitutions. The amyloid-driving mutations are not necessarily involved in propagating fibril formation by providing specific side chain interactions within the fibril structure. Rather, they destabilize the V(L) domain in a specific way, increasing the dynamics of framework regions, which can then change their conformation to form the fibril core. These findings reveal unexpected influences of CDR-framework interactions on antibody architecture, stability, and amyloid propensity. American Society for Biochemistry and Molecular Biology 2021-01-26 /pmc/articles/PMC7949129/ /pubmed/33508322 http://dx.doi.org/10.1016/j.jbc.2021.100334 Text en © 2021 Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Rottenaicher, Georg J.
Weber, Benedikt
Rührnößl, Florian
Kazman, Pamina
Absmeier, Ramona M.
Hitzenberger, Manuel
Zacharias, Martin
Buchner, Johannes
Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains
title Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains
title_full Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains
title_fullStr Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains
title_full_unstemmed Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains
title_short Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains
title_sort molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949129/
https://www.ncbi.nlm.nih.gov/pubmed/33508322
http://dx.doi.org/10.1016/j.jbc.2021.100334
work_keys_str_mv AT rottenaichergeorgj molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains
AT weberbenedikt molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains
AT ruhrnoßlflorian molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains
AT kazmanpamina molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains
AT absmeierramonam molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains
AT hitzenbergermanuel molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains
AT zachariasmartin molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains
AT buchnerjohannes molecularmechanismofamyloidogenicmutationsinhypervariableregionsofantibodylightchains